July 2019

Home  /  2019  /  July

This is the pharmaceutical Joint Assessment PTJA07 – on ustekinumab for the treatment of ulcerative colitis (UC). In September 2019, EMA approved the extension of the indication for ustekinumab to include treatment of adult patients with moderately to severely active

We are pleased to announce that, as of today, the draft methodological guideline "Practical considerations when critically assessing economic evaluations", produced within WP6 B2, has entered the public consultation phase. This consultation will be open until 11th October, 2019.   Objective of the

The methodological guideline ''Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness” is currently under revision by IQWiG, NIPHNO and AETSA. It will be made available for public consultation as of beginning of August for

This is a friendly reminder that EUnetHTA recently started a new Joint Assessment on a medicinal product for neovascular (wet) age-related macular degeneration (AMD). To find out about participation, please read more here. Please be advised that input submissions will be received through

We are pleased to announce that the final assessment for OTCA15 “Irreversible electroporation in liver and pancreatic cancer", together with the input from external experts and manufacturers, are now available for access. Irreversible electroporation (IRE) is a nonthermal ablative method based on